Medical Patent News

RSS

Therapies to target self-renewing population of chemotherapy-resistant cells needed

Leukemia patients whose cancers express higher levels of genes associated with cancer stem cells have a significantly poorer prognosis than patients with lower levels of the genes, say researchers at the Stanford University School of Medicine. The finding is among the first to show that the cancer stem cell hypothesis - which posits that some cancers spring from and are replenished by a small, hardy population of self-renewing cells - can be used to predict outcomes in a large group of patients and one day to tailor treatments in the clinic.

22 Dec 2010

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).

22 Dec 2010

USPTO validates Spectros white LED patent during reexamination

A core Spectros white LED patent was validated during reexamination by the United States Patent Office, and will reissue next year.

22 Dec 2010

3M sues Andover for patent infringement over two layer compression bandage systems

3M and 3M Innovative Properties Co. filed a lawsuit in the U.S. District Court for the District of Minnesota today against Andover Healthcare Inc. seeking a preliminary injunction as well as a permanent injunction and damages regarding Andover's two layer compression bandage systems.

22 Dec 2010

Jazz Pharmaceutical receives USPTO patent for Xyrem oral solution

Jazz Pharmaceuticals, today announced that the United States Patent and Trademark Office has issued a patent related to Xyrem oral solution titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt for the Treatment of Narcolepsy."

22 Dec 2010

ICU Medical wins I.V. connector patent infringement suit against RyMed

ICU Medical, Inc., a leading manufacturer of safe medical connectors, custom medical products and critical care devices, recently secured a victory in a patent infringement case against RyMed Technologies, Inc.

21 Dec 2010

Deinove to receive European patent for genetic engineering process

Deinove, the world's leading specialist in Deinococcus bacteria for biofuels, green chemistry and antibiotics, today announced that the European Patent Office had notified it of the intention to grant the patent application EP2016183 entitled "Process for chromosome engineering using a novel DNA repair system".

21 Dec 2010

OXIS International files patent application to strengthen Ergothioneine intellectual property portfolio

OXIS International, Inc., today announced that is has filed a patent application titled "Methods and Compositions Using Ergothioneine to Treat a Variety of Health Related Factors" with the U.S. Patent and Trademark Office (USPTO).

20 Dec 2010

Response Biomedical strengthens patent protection for RAMP technology

Response Biomedical Corporation today announced that the United States Patent and Trademark Office issued an official Notice of Allowance on one of the Company's patent applications regarding the RAMP® technology. The patent entitled "Comparative Multiple Analyte Immunoassay" is expected to issue in the first quarter of 2011.

20 Dec 2010

Mylan confirms lawsuit by Shionogi Pharma and CIMA LABS relating to generic Orapred ODT ANDA

Mylan Inc. today confirmed that the company and its subsidiary Mylan Pharmaceuticals Inc. have been sued by Shionogi Pharma Inc. and CIMA LABS INC. in connection with the filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg and 30 mg.

17 Dec 2010

Lightlake acquires US Patent for method of terminating methadone maintenance

Lightlake Therapeutics Inc has acquired US Patent 5,587,381, entitled: 'Method for terminating methadone maintenance through extinction of the opiate-taking responses', using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines.

17 Dec 2010

Celator granted U.S. Patent covering CombiPlex technology platform

Celator Pharmaceuticals today announced the United States Patent and Trademark Office issued U.S Patent No. 7,850,990. This patent adds to the intellectual property surrounding Celator's innovative technology platforms and products.

17 Dec 2010

BioMimetic granted Canadian notice of patent allowance covering rhPDGF-BB platform technology formulations

BioMimetic Therapeutics, Inc. announced today the Canadian Intellectual Property Office (CIPO) has allowed patent application No. 2,583,823 titled "Platelet Derived Growth Factor (PDGF) Compositions and Methods of Use Thereof". The new patent will remain in force until October 2025, during which time it will prohibit the marketing of similar or generic versions of the Company's Augment™ orthopedic product line and certain other rhPDGF-BB product formulations.

17 Dec 2010

COPAN announces US patent for evoluton in flocked swab technology

COPAN has enjoyed widespread use of its flocked swabs line, branded as FLOQSwabs, in microbiology for the collection and transportation of bacterial and viral samples.

17 Dec 2010

Orthofix settles Trinity Evolution patent infringement suit with NuVasive and Osiris

Orthofix International N.V. today announced an internal reorganization designed to streamline operations within its three Global Business Units: Spine, Orthopedics and Sports Medicine. The Company expects to record a charge related to employee termination benefits of approximately $4.0 million ($2.4 million net of tax, or $0.13 per diluted share) in the fourth quarter of 2010 in connection with the reorganization.

16 Dec 2010

Generex's buccal drug delivery platform technologies receive new patent

Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) announced today that it has received a new patent for its buccal drug delivery platform technologies. The Canadian Intellectual Property Office has granted to Generex Canadian Patent No. 2,354,148, a patent titled Aerosol Formulations for Buccal and Pulmonary Application.

16 Dec 2010

Court dismisses Illumina's patent infringement lawsuits against Affymetrix

Affymetrix, Inc. today announced that the U.S. District Court for the Western District of Wisconsin (the "Court") has granted the company's motion for summary judgment that Affymetrix does not infringe the patents held by Illumina, Inc., and has directed that the patent infringement lawsuits brought against the company by Illumina regarding U.S. Patent Nos. 7,510,841 and 7,612,020 be dismissed and the cases closed.

From Illumina, Inc. 15 Dec 2010

Cell Biosciences receives US Patent for NanoPro assay technology

Cell Biosciences, Inc. today announced the issuance of Patent No. 7,846,676 for "Methods and Devices for Analyte Detection" by the United States Patent and Trademark Office.

15 Dec 2010

Watson files generic Exalgo ANDA, confirms patent challenge from Mallinckrodt

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Hydromorphone Hydrochloride Extended-release Tablets, 8 mg, 12 mg, and 16 mg.

14 Dec 2010

NinePoint enters IP licensing agreement with Massachusetts General Hospital

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology medical devices, today announced it has entered into an intellectual property (IP) licensing agreement with Massachusetts General Hospital (MGH). Under the agreement, NinePoint has certain exclusive rights in multiple fields to 188 patents and patent applications owned by MGH.

13 Dec 2010

Medical Patent News

Therapies to target self-renewing population of chemotherapy-resistant cells needed

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

USPTO validates Spectros white LED patent during reexamination

3M sues Andover for patent infringement over two layer compression bandage systems

Jazz Pharmaceutical receives USPTO patent for Xyrem oral solution

ICU Medical wins I.V. connector patent infringement suit against RyMed

Deinove to receive European patent for genetic engineering process

OXIS International files patent application to strengthen Ergothioneine intellectual property portfolio

Response Biomedical strengthens patent protection for RAMP technology

Mylan confirms lawsuit by Shionogi Pharma and CIMA LABS relating to generic Orapred ODT ANDA

Lightlake acquires US Patent for method of terminating methadone maintenance

Celator granted U.S. Patent covering CombiPlex technology platform

BioMimetic granted Canadian notice of patent allowance covering rhPDGF-BB platform technology formulations

COPAN announces US patent for evoluton in flocked swab technology

Orthofix settles Trinity Evolution patent infringement suit with NuVasive and Osiris

Generex's buccal drug delivery platform technologies receive new patent

Court dismisses Illumina's patent infringement lawsuits against Affymetrix

Cell Biosciences receives US Patent for NanoPro assay technology

Watson files generic Exalgo ANDA, confirms patent challenge from Mallinckrodt

NinePoint enters IP licensing agreement with Massachusetts General Hospital

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News